WAL 0623
Alternative Names: WAL-0623Latest Information Update: 04 Feb 2025
Price :
$50 *
At a glance
- Originator Walden Biosciences
- Class Small molecules
- Mechanism of Action Dynamin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Proteinuria
Most Recent Events
- 10 Jan 2025 Preclinical trials in Proteinuria in USA (PO), before January 2025
- 10 Jan 2025 Pharmacodynamics data from a preclinical trial in Proteinuria released by Walden Biosciences (Walden Biosciences pipeline, January 2025)
- 10 Jan 2025 Walden Biosciences plans a first-in-human phase I trial in Proteinuria (PO) in 2025